Anthony K Park

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1289479/publications.pdf Version: 2024-02-01



ANTHONY K DADK

#	Article	IF	CITATIONS
1	Regional Delivery of Chimeric Antigen Receptor–Engineered T Cells Effectively Targets HER2+ Breast Cancer Metastasis to the Brain. Clinical Cancer Research, 2018, 24, 95-105.	7.0	220
2	Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors. Science Translational Medicine, 2020, 12, .	12.4	140
3	Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancer. Oncolmmunology, 2018, 7, e1380764.	4.6	111
4	Pre-conditioning modifies the TME to enhance solid tumor CAR TÂcell efficacy and endogenous protective immunity. Molecular Therapy, 2021, 29, 2335-2349.	8.2	51
5	Novel oncolytic chimeric orthopoxvirus causes regression of pancreatic cancer xenografts and exhibits abscopal effect at a single low dose. Journal of Translational Medicine, 2018, 16, 110.	4.4	33
6	Novel Chimeric Immuno-Oncolytic Virus CF33-hNIS-antiPDL1 for the Treatment of Pancreatic Cancer. Journal of the American College of Surgeons, 2020, 230, 709-717.	0.5	30
7	Oncolytic poxvirus CF33-hNIS-ΔF14.5 favorably modulates tumor immune microenvironment and works synergistically with anti-PD-L1 antibody in a triple-negative breast cancer model. Oncolmmunology, 2020, 9, 1729300.	4.6	29
8	A Novel Oncolytic Chimeric Orthopoxvirus Encoding Luciferase Enables Real-Time View of Colorectal Cancer Cell Infection. Molecular Therapy - Oncolytics, 2018, 9, 13-21.	4.4	28
9	Recombinant Orthopoxvirus Primes Colon Cancer for Checkpoint Inhibitor and Cross-Primes T Cells for Antitumor and Antiviral Immunity. Molecular Cancer Therapeutics, 2021, 20, 173-182.	4.1	20
10	CF33-hNIS-antiPDL1 virus primes pancreatic ductal adenocarcinoma for enhanced anti-PD-L1 therapy. Cancer Gene Therapy, 2022, 29, 722-733.	4.6	10
11	PET imaging and treatment of pancreatic cancer peritoneal carcinomatosis after subcutaneous intratumoral administration of a novel oncolytic virus, CF33-hNIS-antiPDL1. Molecular Therapy - Oncolytics, 2022, 24, 331-339.	4.4	6
12	Toward comprehensive imaging of oncolytic viroimmunotherapy. Molecular Therapy - Oncolytics, 2021, 23, 303-310.	4.4	4
13	Priming stroma with a vitamin D analog to optimize viroimmunotherapy for pancreatic cancer. Molecular Therapy - Oncolytics, 2022, 24, 864-872.	4.4	3
14	Abstract 1155: Subcutaneous intratumoral administration of a novel oncolytic virus leads to eradication of peritoneal disseminated pancreatic cancer in nude mice. , 2021, , .		0